本文選題：Cyclin + D1��； 參考：《青島大學(xué)》2017年碩士論文

【摘要】：目的:(1)探討乳腺癌低危組、中危組、高危組患者中細(xì)胞周期蛋白(Cyclin D1)以及胸腺激酶1(TK1)的不同表達(dá)情況;(2)比較Cyclin D1以及TK1與患者年齡的大小、淋巴結(jié)是否轉(zhuǎn)移、腫瘤的大小、TNM分期、組織學(xué)的分級(jí)表達(dá)、ER、PR、C-erb B-2等臨床病理參數(shù)的關(guān)系;(3)探討Cyclin D1以及TK1的表達(dá)與乳腺癌的臨床意義。方法:(1)選擇乳腺手術(shù)切除的病例標(biāo)本共計(jì)87例,均來自文登區(qū)人民醫(yī)院普外科,并且已取得患者及家屬的同意,簽定文登區(qū)人民醫(yī)院的相關(guān)知情文件的同意書,且通過文登區(qū)人民醫(yī)院的倫理委員會(huì)的標(biāo)準(zhǔn)。(2)常規(guī)病理檢查結(jié)果采用半定量的組織學(xué)分級(jí)的方法判斷,然后按2005St.Gallen國際乳腺癌治療共識(shí)按患者年齡、臨床分期、腋窩淋巴結(jié)轉(zhuǎn)移、病理學(xué)的分級(jí)HER-2表達(dá)等指標(biāo)將患有乳腺惡性腫瘤的病人分為低危組、中危組、高危組三組。(3)各病理類型組織均是采用免疫組化的方法檢測Cyclin D1以及TK1的表達(dá)情況;比較Cyclin D1以及TK1在乳腺惡性腫瘤低危組、中危組、高危組三組的表達(dá)情況;比較Cyclin D1以及TK1二者與臨床各病理學(xué)指標(biāo)(比如:患者的年齡大小、淋巴結(jié)是否轉(zhuǎn)移、腫瘤的大小、TNM分期、組織學(xué)的分級(jí)表達(dá)、ER、PR、C-erb B-2)的關(guān)系。(4)運(yùn)用SPSS17.0統(tǒng)計(jì)軟件包對Cyclin D1以及TK1與乳腺癌病人臨床病理參數(shù)之間的關(guān)系以及兩種對乳腺癌預(yù)后的影響進(jìn)行分析。結(jié)果:(1)Cyclin D1陽性(+)為細(xì)胞核染色,陽性的表達(dá)率為83.9%(73/87)。Cyclin D1陽性(+)表達(dá)的結(jié)果與ER有明顯差異(P0.05);但與患者年齡的大小、淋巴結(jié)是否轉(zhuǎn)移、腫瘤的大小、TNM分期、組織學(xué)的分級(jí)表達(dá)、PR、C-erb B-2沒有相關(guān)性(P0.05)。在乳腺癌患者低危組、中危組、高危組中Cyclin D1表達(dá)水平由低到高依次為低危組中危組高危組。(2)TK1陽性(+)為細(xì)胞質(zhì)染色,陽性的表達(dá)率為77%(67/87)。TK1陽性(+)表達(dá)與與組織學(xué)分級(jí)表達(dá)有差異(P0.05);但與患者的年齡大小、淋巴結(jié)是否轉(zhuǎn)移、腫瘤的大小、TNM分期、ER、PR、C-erb B-2無相關(guān)性(P0.05)。在乳腺癌患者低危組、中危組、高危組中TK1表達(dá)水平由低到高依次為低危組中危組高危組。結(jié)論:Cyclin D1和TK1在乳腺癌組織中呈高表達(dá)狀態(tài),Cyclin D1和TK1呈現(xiàn)明顯正相關(guān)關(guān)系,提示Cyclin D1和TK1在乳腺癌的發(fā)生、發(fā)展過程中有意義。
[Abstract]:Objective to investigate the different expression of cyclin D1 and TK1 in low risk group, moderate risk group, high risk group and high risk group. The clinical significance of the expression of Cyclin D1 and TK1 in breast cancer was studied. Methods A total of 87 cases of breast surgery were selected, all from the Department of General surgery of the people's Hospital of Wenten District. The consent of the patients and their families was obtained, and the consent of the relevant informed documents of the people's Hospital of Wenteng District was signed. The results of routine pathological examination were judged by semi-quantitative histological grading, and then according to the international consensus of 2005St.Gallen, according to the age, clinical stage, axillary lymph node metastasis, the results of routine pathological examination were judged by the standard of ethics committee of Wendeng District people's Hospital. The patients with breast cancer were divided into three groups: low risk group, middle risk group and high risk group. The expression of Cyclin D1 and TK1 was detected by immunohistochemical method. To compare the expression of Cyclin D1 and TK1 in low risk group, middle risk group and high risk group, and to compare the expression of Cyclin D1 and TK1 with the clinicopathological indexes (such as age, lymph node metastasis or not). The relationship between tumor size and TNM stage, histological grade expression of ERA PRERB B 2) and the relationship between Cyclin D1 and TK1 and the clinicopathological parameters of breast cancer patients and their influence on the prognosis of breast cancer were analyzed by SPSS 17.0 software package. Results the positive expression rate of Cyclin D1 was 83.9% and the positive rate of Cyclin D1 was significantly different from that of ER (P 0.05), but it was significantly different from that of ER in age, lymph node metastasis, tumor size and TNM stage. The histologically graded expression of PRA C-erb B-2 was not correlated with P0.05. In low risk group, moderate risk group and high risk group, the expression of Cyclin D1 in low risk group, middle risk group and high risk group was in order of Cyclin D1 positive staining in low risk group, middle risk group, high risk group and high risk group. The positive expression rate of TK1 was 77 / 87. TK1 positive expression was significantly different from histological grade expression (P 0.05), but had no correlation with age, lymph node metastasis, tumor size, TNM stage, ERP PRA C-erb B-2, and P0.05P 0. 05, P 0. 05, P 0. 05, P 0. 05, P 0. 05, P 0. 05, P 0. 05, P 0. 05, P 0. 05 and P 0. 05, respectively. The expression of TK1 in low risk group, middle risk group and high risk group was in order of low risk group, middle risk group and high risk group. Conclusion there is a significant positive correlation between Cyclin D1 and TK1 in breast cancer tissues, suggesting that Cyclin D1 and TK1 may play an important role in the occurrence and development of breast cancer.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 周玉麗;劉瑩瑩;徐金鋒;;趨化因子與乳腺癌關(guān)系的研究進(jìn)展[J];廣東醫(yī)學(xué);2015年24期

2 楊光倫;陳茂山;;乳腺包塊的影像學(xué)診斷[J];中國普外基礎(chǔ)與臨床雜志;2015年06期

3 楊后圃;王殊;;當(dāng)今乳腺外科熱點(diǎn)問題與發(fā)展趨勢[J];腫瘤防治研究;2015年05期

4 白夏楠;姜永冬;劉通;吳昊;張金鋒;龐達(dá);;2q35 rs13387042和8q24 rs13281615單核苷酸多態(tài)性與中國東北漢族絕經(jīng)前婦女乳腺癌風(fēng)險(xiǎn)關(guān)系[J];中國癌癥雜志;2014年09期

5 張劍;胡夕春;;分子分型時(shí)代乳腺癌的內(nèi)科治療——輔助治療和姑息治療在探索中前行[J];中國癌癥雜志;2012年10期

6 陳旭東;劉寶鳳;賈淑媛;;癌性疲乏干預(yù)對提高乳腺癌術(shù)后患者生存質(zhì)量的效果研究[J];中華現(xiàn)代護(hù)理雜志;2012年03期

7 鄭瑩;吳春曉;吳凡;;中國女性乳腺癌死亡現(xiàn)況和發(fā)展趨勢[J];中華預(yù)防醫(yī)學(xué)雜志;2011年02期

8 劉衛(wèi)梅;劉建民;封琳;付剛;;ER、PR及PS_2基因在乳腺癌中的表達(dá)及其臨床意義[J];中國實(shí)用醫(yī)藥;2008年35期

9 任占平;石U，

本文編號(hào)：2021436